|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Pneumococcal vaccination during pregnancy for preventing infant infectionChaithongwongwatthana S, Yamasmit W, Limpongsanurak S, Lumbiganon P, DeSimone JA, Baxter JK, Tolosa JE
Bookmark this:
     more ...
SummaryPneumococcal vaccination during pregnancy for preventing infant infectionNot enough evidence to support the use of pneumococcal vaccination during pregnancy for preventing infant infections. Although the incidence of invasive pneumococcal disease is variable across the world, mortality rate is high in children who get this infection. Newborn vaccination schedules could reduce the impact of pneumococcal disease in immunized children, but have no effect on the morbidity and mortality of infants less than three months of age. Maternal pneumococcal immunization during pregnancy may be a method of preventing pneumococcal disease during the infant's first months of life. The review of trials found there was not enough information to say whether pneumococcal vaccination during pregnancy led to fewer infant infections.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
January 25. 2006 AbstractBackgroundEach year at least one million children worldwide die of pneumococcal infections. The development of bacterial resistance to antimicrobials adds to the difficulty of treatment of diseases and emphasizes the need for a preventive approach. Newborn vaccination schedules could substantially reduce the impact of pneumococcal disease in immunized children, but does not have an effect on the morbidity and mortality of infants less than three months of age. Pneumococcal vaccination during pregnancy may be a way of preventing pneumococcal disease during the first months of life before the pneumococcal vaccine administered to the infant starts to produce protection. ObjectivesTo assess the effect of pneumococcal vaccination during pregnancy for preventing infant infection. Search strategyWe searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2004), CENTRAL (The Cochrane Library, Issue 2, 2004), MEDLINE (January 1966 to June 2004), EMBASE (January 1985 to June 2004), and reference lists of articles. We updated the search of the Cochrane Pregnancy and Childbirth Group's Trials Register on 1 October 2009 and added the results to the awaiting classification section. Selection criteriaRandomized controlled trials in pregnant women comparing pneumococcal vaccine with placebo or doing nothing or with another vaccine to prevent infant infections. Data collection and analysisTwo authors independently assessed methodological quality and extracted data using a data collection form. Study authors were contacted for additional information. Main resultsThree trials (280 participants) were included. There was no evidence that pneumococcal vaccination during pregnancy reduces the risk of neonatal infection (one trial, 149 pregnancies, relative risk (RR) 0.51; 95% confidence interval (CI) 0.18 to 1.41). Although the data suggest an effect in reducing pneumococcal colonisation in infants by 16 months of age (one trial, 56 pregnancies, RR 0.33; 95% CI 0.11 to 0.98), there was no evidence of this effect in infants at two months of age (RR 0.28; 95% CI 0.02 to 5.11) or by seven months of age (RR 0.32; 95% CI 0.08 to 1.29). Authors' conclusionsThere is insufficient evidence to support whether pneumococcal vaccination during pregnancy could reduce infant infections. [Note: The four citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.] |